Hostname: page-component-76fb5796d-dfsvx Total loading time: 0 Render date: 2024-04-26T16:41:52.442Z Has data issue: false hasContentIssue false
  • English
  • Français

Factors Associated with Concomitant Psychotropic Drug Use in the Treatment of Major Depression: A STAR*D Report

Published online by Cambridge University Press:  07 November 2014

Richard C. Shelton ,
Steve D. Hollon ,
Stephen R. Wisniewski ,
Jonathan E. Alpert ,
G.K. Balasubramani ,
Edward S. Friedman ,
A. John Rush ,
Madhukar H. Trivedi  and
Sheldon H. Preskorn
Get access Rights & Permissions [Opens in a new window]

Abstract

Introduction: Concomitant psychotropic medication (CPM) treatment is common in persons with major depression (MDD). However, relationships with patient characteristics and response to treatment are unclear.

Methods: Participants with nonpsychotic MDD (N=2682) were treated with citalopram, 20–60 mg/day. Sociodemographic, clinical, and treatment outcome characteristics were compared between those using CPMs at study entry or during up to 14 weeks of citalopram treatment, and non-users.

Results: About 35% of participants used a CPM. Insomnia was the predominant indication (70.3%). CPM users were more likely to be seen in primary care settings (69.3% versus 30.7%), be white, of non-Hispanic ethnicity, married, and have a higher income, private insurance, and certain comorbid disorders. CPM users had greater depressive severity, poorer physical and mental functioning, and poorer quality of life than non-users. Response and remission rates were also lower. CPM users were more likely to achieve ≥50 mg/day of citalopram, to report greater side effect intensity, and to have serious adverse events, but less likely to be intolerant of citalopram.

Conclusion: CPMs are associated with greater illness burden, more Axis I comorbidities (especially anxiety disorders), and lower treatment effectiveness. This suggests that CPM use may identify a more difficult to treat population that needs more aggressive treatment.

Type
Original Research
Information
CNS Spectrums , Volume 14 , Issue 9 , September 2009 , pp. 487 - 498
Copyright
Copyright © Cambridge University Press 2009

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1.Valenstein, M, Taylor, KK, Austin, K, Kales, HC, McCarthy, JF, Blow, FC. Benzodiazepine use among depressed patients treated in mental health settings. Am J Psychiatry. 2004;161:654–661.CrossRefGoogle ScholarPubMed
2.Clark, RE, Xie, H, Brunette, MF. Benzodiazepine prescription practices and substance abuse in persons with severe mental illness. J Clin Psychiatry. 2004;65:151–155.Google Scholar
3.Brunette, MF, Noordsy, DL, Xie, H, Drake, RE. Benzodiazepine use and abuse among patients with severe mental illness and co-occurring substance use disorders. Psychiatr Serv. 2003;54:1395–1401.CrossRefGoogle ScholarPubMed
4.Roeloffs, CA, Wells, KB, Ziedonis, D, Tang, L, Unutzer, J. Problem substance use among depressed patients in managed primary care. Psychosomatics. 2002;405–412.Google Scholar
5.Goodwin, GM. Neuropsychological and neuroimaging evidence for the involvement of the frontal lobes in depression. J Psychopharmacol. 1997;11:115–122.Google Scholar
6.Landry, MJ, Smith, DE, Steinberg, JR. Anxiety, depression, and substance use disorders: diagnosis, treatment, and prescribing practices. J Psychoactive Drugs. 1991;23:397–416.Google Scholar
7.Bingefors, K, Isacson, D, Von Knorring, L, Smedby, B, Ekselius, L, Kupper, LL. Antidepressant-treated patients in ambulatory care long-term use of non-psychotropic and psychotropic drugs. Br J Psychiatry. 1996;168:292–298.Google Scholar
8.Alonso, J, Angermeyer, MC, Bernert, S, et al.Psychotropic drug utilization in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand Suppl. 2004;420:55–64.Google Scholar
9.Rascati, K. Drug utilization review of concomitant use of specific serotonin reuptake inhibitors or clomipramine with antianxiety/sleep medications. Clin Ther. 1995;17:786–790.Google Scholar
10.Hales, RE, Hilty, DM, Brunson, GH. Cost savings with nefazodone in treating depression. J Clin Psychiatry. 2002;63(Suppl 1):48–51.Google ScholarPubMed
11.Fava, M, Rush, AJ, Trivedi, MH, et al.Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study. Psychiatr Clin North Am. 2003;26:457–494.Google Scholar
12.Rush, AJ, Fava, M, Wisniewski, SR, et al.Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Control Clin Trials. 2004;25:119–142.Google Scholar
13.Hamilton, M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56–62.CrossRefGoogle ScholarPubMed
14.Williams, JBW. A structured interview guide for the Hamilton Depression Rating Scale. Arch Gen Psychiatry. 1988;45:742–747.CrossRefGoogle ScholarPubMed
15.Zimmerman, M, Mattia, JI. A self-report scale to help make psychiatric diagnoses: the Psychiatric Diagnostic Screening Questionnaire. Arch Gen Psychiatry. 2001;58:787–794.CrossRefGoogle ScholarPubMed
16.Zimmerman, M, Mattia, JI. The Psychiatric Diagnostic Screening Questionnaire: development, reliability and validity. Compr Psychiatry. 2001;42:175–189.CrossRefGoogle ScholarPubMed
17.Trivedi, MH, Rush, AJ, Ibrahim, HM, et al.The Inventory of Depressive Symptomatology, Clinician Rating (IDS-C) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: a psychometric evaluation. Psychol Med. 2004;34:73–82.Google Scholar
18.Rush, AJ, Trivedi, MH, Ibrahim, HM, et al.The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry. 2003;54:573–583.CrossRefGoogle ScholarPubMed
19.Rush, AJ, Gullion, CM, Basco, MR, Jarrett, RB, Trivedi, MH. The Inventory of Depressive Symptomatology (IDS): psychometric properties. Psychol Med. 1996;26:477–486.CrossRefGoogle ScholarPubMed
20.Rush, AJ, Bernstein, IH, Trivedi, MH, et al.An evaluation of the quick inventory of depressive symptomatology and the hamilton rating scale for depression: a sequenced treatment alternatives to relieve depression trial report. Biol Psychiatry. 2006;59:493–501.CrossRefGoogle ScholarPubMed
21.Mundt, JC. Interactive voice response systems in clinical research and treatment. Psychiatr Serv. 1997;48:611–612.Google ScholarPubMed
22.Ware, J Jr., Kosinski, M, Keller, SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care. 1996;34:220–233.CrossRefGoogle ScholarPubMed
23.Endicott, J, Nee, J, Harrison, W, Blumenthal, R. Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacol Bull. 1993;29:321–326.Google Scholar
24.Mundt, JC, Marks, IM, Shear, MK, Greist, JH. The Work and Social Adjustment Scale: a simple measure of impairment in functioning. Br J Psychiatry. 2002;180:461–464.CrossRefGoogle Scholar
25.Reilly, MC, Zbrozek, AS, Dukes, EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993;4:353–365.CrossRefGoogle ScholarPubMed
26.Wisniewski, SR, Rush, AJ, Balasubramani, GK, Trivedi, MH, Nierenberg, AA. Selfrated global measure of the frequency, intensity, and burden of side effects. J Psychiatr Pract. 2006;12:71–79.CrossRefGoogle ScholarPubMed
27.Trivedi, MH, Rush, AJ, Wisniewski, SR, et al.Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163:28–40.CrossRefGoogle ScholarPubMed
28.Rush, AJ, Trivedi, MH, Wisniewski, SR, et al.Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med. 2006;354:1231–1242.CrossRefGoogle ScholarPubMed
29.Trivedi, MH, Fava, M, Wisniewski, SR, et al.Medication augmentation after the failure of SSRIs for depression. N Engl J Med. 2006;354:1243–1252.CrossRefGoogle ScholarPubMed
30.Kendler, KS, Heath, AC, Neale, MC, Kessler, RC, Eaves, LJ. Alcoholism and major depression in women. A twin study of the causes of comorbidity. Arch Gen Psychiatry. 1993;50:690–698.Google Scholar
31.Swendsen, JD, Merikangas, KR, Canino, GJ, Kessler, RC, Rubio-Stipec, M, Angst, J. The comorbidity of alcoholism with anxiety and depressive disorders in four geographic communities. Compr Psychiatry. 1998;39:176–184.Google Scholar
32.Grant, BF. Comorbidity between DSM-IV drug use disorders and major depression: results of a national survey of adults. J Subst Abuse. 1995;7:481–497.CrossRefGoogle ScholarPubMed